We’re looking forward to seeing you in Orlando, Florida, for the HealthTrust University Conference. From August 12-13 we’ll be sharing about oncology solutions at booth #1024.
NeoGenomics Laboratories’ Post
More Relevant Posts
-
At the 2023 CPC+CBEx conference, Todd Schonherz, AON CEO, spoke in a session titled "Healthcare Industry Consolidation: The Impact on Cancer Care and Strategic Partnerships" on industry consolidation and the different strategies community oncology practices can use to their advantage. Watch the video > https://hubs.li/Q029LZ_50
To view or add a comment, sign in
-
At the 2023 CPC+CBEx conference, Todd Schonherz, AON CEO, spoke in a session titled "Healthcare Industry Consolidation: The Impact on Cancer Care and Strategic Partnerships" on industry consolidation and the different strategies community oncology practices can use to their advantage. Watch the video > https://hubs.li/Q029LZ_50
At the 2023 CPC+CBEx conference, Todd Schonherz, AON CEO, spoke in a session titled "Healthcare Industry Consolidation: The Impact on Cancer Care and Strategic Partnerships" on industry consolidation and the different strategies community oncology practices can use to their advantage. Watch the video > https://hubs.li/Q029LZ_50
To view or add a comment, sign in
-
Are you a leader at a patient organization? If so, you won’t want to miss the third installment of our five-part Patient Organization Webinar Series. Join fellow leaders for Changing Oncology Landscape: Considerations for Oncology Organizations and Registries. 📅 Wednesday, June 26, 2024, 11:00 AM EDT 📌 Webinar 🎙️ Audra Moran, Kapila Viges, Jeff Hodge, Murray Aitken 🔗 Register here: https://lnkd.in/ehRnEdkj #PatientAdvocacy #PatientOutcomes
To view or add a comment, sign in
-
-
Drug revenue is projected to account for 90% of the average practice's total revenue in 2023, according to our estimates. Drop a note below if you are interested in accessing more in-depth analysis of the significance of cancer drug revenues in community practices. https://okt.to/zv3JX8 #marketaccess #communityoncology #marketaccessinsights #drugrevenuetrends
To view or add a comment, sign in
-
-
Thank you to those on my feed who reminded me of #NationalPetDay. Everyone meet Luna. Her favorite thing is co-marketing the solid tumor GDUs! 🙂 Shameless plug from Luna: “Check out our upcoming debates calendar! Mark your calendars & get ready to elevate your knowledge and expertise in the field of oncology & secure free registration for clinicians. ➡️ greatdebatesandupdates.com”
To view or add a comment, sign in
-
-
Unfortunately in some states, too many well-meaning policymakers are missing the facts. This is a vital federal program that Congress needs to fix. Large hospitals are buying deeply discounted 340B medicines and then turning around and charging both uninsured patients and insurance companies higher prices, pocketing the difference with little to no evidence they use that money to help patients the program is meant to aid. How many people are aware that many 340B hospitals are contracting with pharmacies owned by pharmacy benefit managers (PBMs) to dispense 340B medicines? How many know that these chain pharmacies can share in 340B revenues with no strings attached? This includes charging an uninsured individual the full cost of the medicine. Just another way a broken system is helping PBMs to profit off the backs of patients. It’s no wonder Congress, the FTC and others have them under the microscope.
No matter where you stand on #340B, you're probably at least a little uncomfortable with the idea of that program padding the coffers of #PBMs. Yet that appears to be exactly what's happening, per a new Avalere/Community Oncology Alliance analysis. https://lnkd.in/g5sRzWiD
To view or add a comment, sign in
-
-
Strategic marketing leader who delivers insight-led strategies and outcomes for patients and stakeholders who serve them.
Thank you, Stacy Hurt, for helping us all at Parexel stay laser-focused on our North Star—the patients! Your relentless passion for representing the patient perspective has been an inspiration since day one of my journey at Parexel. I'm deeply grateful for your support and significant contributions to our latest New Medicines Novel Insights report! 🔑 "The key to advancing precision oncology is to democratize the data." 🔑 Stacy Hurt, Parexel's Chief Patient Officer and a stage 4 cancer survivor, highlights three things we MUST do to ensure all patients can potentially benefit from precision oncology in our New Medicines, Novel Insights report: https://lnkd.in/gJWamVHP #PatientData #Oncology #patientsfirst #NovelInsights
To view or add a comment, sign in
-
Attending the 16th Annual AACI (Association of American Cancer Institutes) CRI Meeting in Rosemont next week? Come visit the RealTime team to learn more about how our family of brands and products, including Devana's category-defining PROPEL platform, can help transform your clinical trial process from start to finish! #clinicaltrials #clinicalresearch #clinicaltrialsoftware #PROPEL
To view or add a comment, sign in
-
-
When asked about Medrio, Stacey King immediately mentions customer focus, great technology, and helpful staff. Hear more about how she's felt empowered by Medrio over the years in managing oncology #ClinicalTrials and more! #CancerResearch #ClinicalResearch #ClinicalTrialTechnology
To view or add a comment, sign in
-
#DidYouKnow – there are #ClinicalTrials available for every step of a patient’s cancer journey and all stages of melanoma. You can join a clinical trial before or after trying other FDA-approved treatments. In partnership with Bristol Myers Squibb, we created this clinical trial infographic to better inform patients, caregivers and our entire #melanoma community about their treatment options - https://buff.ly/43MfoFT
To view or add a comment, sign in